Quarterly report · Q3
9776.TEDINET S100Q4U9
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥15.3bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥19.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.3bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥817m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥1.1bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥972m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥891m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.0bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥493m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥662m | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥578m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥660m | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥16.9bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥16.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥15.5bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.1bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥5.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.8bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥10.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.0bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥147.85 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.53 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.16 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥193.96 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.83 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥75m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥73m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | ¥49m |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥6.4bn |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥6.4bn |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥532m |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥601m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥726m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥495m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥8m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥15.7bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥15.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥495m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥15.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥15.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥498m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-12-31 | ¥80m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-12-31 | ¥79m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥723,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-12-31 | ¥55m |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥5.5bn |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥5.5bn |
| jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥741m |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥7.9bn |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥7.9bn |
| jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥642m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥1.7bn |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥724m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥994m |
| jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥12m |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥15.2bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥14.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥994m |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥15.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥14.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥995m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 387
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)清明監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)岩間 昭 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)島貫 幸治 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 14285788000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 15250105000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 19109595000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 1139476000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 971637000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1605618000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 661798000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 493187000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 1042882000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 635876000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 583358000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 1019339000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 10023609000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 10814977000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 10337959000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 15510626000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 16893292000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 16149449000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 193.96 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 147.85 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 306.16 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.632 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.622 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.626 | |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 59.83 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 70.53 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4216000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4216000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4216000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4216000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 885400 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 3329900 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 33299 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 700 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 4216000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 33299 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 885400 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |